Picture loading failed.

Anti-Influenza A HA2 therapeutic antibody (Pre-made Diridavumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Diridavumab (CR6261) (INN) is a monoclonal antibody designed for the treatment of influenza A.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-147-1mg 1mg 3090
GMP-Bios-ab-147-10mg 10mg 21890
GMP-Bios-ab-147-100mg 100mg 148000
GMP-Bios-ab-147-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-Influenza A HA2 therapeutic antibody (Pre-made Diridavumab biosimilar,Whole mAb)
INN Name Diridavumab
TargetInfluenza A HA2
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI Structure3gbn:HL/3gbm:HL:IM/5c0s:HL
99% SI StructureNone
95-98% SI Structure4evn:AB:CD:IJ:OP:KL:EF:GH:MN
Year Proposed2014
Year Recommended2015
CompaniesNational Institute of Allergy and Infectious Diseases;Crucell
Conditions Approvedna
Conditions ActiveInfluenza A virus (H1N1) infections
Conditions Discontinuedna
Development Techna